Infectious diseases caused by bacterial pathogens are top causes of health complications and mortality in the world
[1]. The pathogens responsible for many human infectious diseases such as urinary tract infection, tuberculosis, gastroenteritis, pneumonia, and wound infections are proven to be highly adept in acquiring mechanisms of antimicrobial resistance
[2],
[3],
[4]. The rapid emergence of multidrug resistant pathogens or “super bugs” is contributed by the widespread injudicious practice of empiric antibiotic usage and infiltration of antibiotics in the food chain, which have accelerated selection and dissemination of resistant pathogens
[5]. Consequently, clinicians have fewer treatment options, particularly in the most needy patients. On the other hand, the excessive cost for developing a new antimicrobial and its short useful lifetime render a poor investment returns. Many pharmaceutical companies have de-emphasized their antimicrobial research programs in the past two decades and only few large firms are currently active in building the clinical antibiotic pipeline. As a result, the constant need for new antibiotics has far outpaced the development of new classes of antimicrobials by the pharmaceutical industry (2 in the last 20 years)
[5],
[6]. This represents a significant threat in public health. Undoubtedly, new sources of antibiotics are highly sought after
[7].
The discovery of antibiotics has been traditionally focused on natural products and semi-synthetic tailoring of these natural compounds chemically. Natural substances produced by microorganisms are the most important source of antibiotics. For example, gentamicin is an aminoglycoside antibiotic targeting bacterial ribosomes and is produced by fermentation using
micromonospora. Many plant-derived materials, such as cinnamon oils and peppermint oils, are also natural antimicrobial agents
[8],
[9],
[10]. In fact, the use of plants with antimicrobial activities for treating wound infections was described in Chinese medicine and other ancient cultures at least 2500 years ago
[11]. After the intensive screening of natural antibiotics in the past 50 years, recent antibiotic research effort is migrating to newer sources of natural antimicrobials, such as cyanobacteria and antimicrobial peptides
[12],
[13]. Synthetic compounds can also provide new avenues in antimicrobials. As an example, sulfamethoxazole is a synthetic antimicrobial that inhibits the folate biosynthetic pathway. Novel libraries of synthetic compounds are being developed to provide improved architectural complexity approaching that of natural products to serve as structural scaffolds for creating new antibiotics
[14].
Combination antimicrobial therapy using synergistic antibiotic cocktails, on the other hand, represents an appealing option for treating bacterial infections
[7]. A finely tuned mixture of drugs, in many cases, is known to be more effective than monotherapy. A well-known success of drug cocktails in disease treatment is in the fight against human immunodeficiency virus, the virus that causes acquired immune deficiency syndrome
[15]. Another example is the treatment of childhood acute lymphoblastic leukemia by the optimization of drug cocktails based on clinical empiricism and trial and error. Evidence for this is seen by the fact that the death rate for acute lymphoblastic leukemia has dropped 90% in the past 25 years
[16]. A key advantage of combination therapy using synergistic, or even additive, cocktails is the reduction in drug concentration, which minimizes the toxicity and side effects of many antimicrobials to the host. For instance, high doses of gentamicin can cause renal failure, and permanent losses of equilibrioception and hearing
[17],
[18]. Combination antimicrobial therapy is, therefore, likely a fruitful option for the treatment of infectious diseases caused by bacterial pathogens. As a matter of fact, co-trimoxazole, a two-drug synergistic combination with trimethoprim and sulphamethoxazole at a 1
![[ratio]](/corehtml/pmc/pmcents/x2236.gif)
5 ratio, is one of the best selling antibiotics for the treatment of various bacterial infections
[19]. Nevertheless, a first hurdle in implementing combination antimicrobial therapy is to identify potent cocktails out of a large number of possible drug combinations. It is difficult to predict synergistic activities between different antimicrobials by studying them individually. Furthermore, the optimal dose of a drug individually could often be different from the most effective dose in a potent cocktail. Identifying potent cocktails out of different concentrations of various antibiotics represent a classical combinatorial optimization problem and the possible combinations increases rapidly with the number of antimicrobials being considered
[20],
[21]. A systematic procedure for rapidly determining synergistic antimicrobial cocktails is, therefore, necessary to accelerate our progress in combination antimicrobial therapy. In addition, rapid determination of potent antimicrobial cocktails will also improve our ability to promptly response to multidrug resistant pathogens and biological warfare agents in emergency situations and high-risk areas such as temporary clinics established in response to natural and man-made disasters.
Optimization strategies in engineering and computer sciences are well-established approaches for controlling highly complex systems and will likely play an essential role in numerous biomedical sciences and clinical applications
[20],
[21],
[22],
[23],
[24],
[25]. For instance, search algorithms, which iteratively determine the optimal solutions (drug cocktails) in the parametric spaces (different drug combinations), can be applied for determining synergistic drug combinations. A closed-loop optimization strategy was demonstrated for rapid screening of antiviral drug cocktails and identifying cytokine combinations to regulate the NF-κB using signal transduction pathway using a stochastic search algorithm, Gur Game
[26]. A Medicinal Algorithmic Combinatorial Screen based on the hill climbing algorithm was demonstrated for screening anti-cancer drug cocktails
[27]. A parallel search scheme, Differential Evolution algorithm, was demonstrated for identifying antiviral cocktails for Kaposi's Sarcoma-associated Herpesvirus
[28]. These search algorithms, which test drug cocktails sequentially, are especially effective for biological systems with smooth response surfaces in the parametric space. Due to the urgency of many infectious diseases, a metamodel antimicrobial cocktail optimization (MACO) scheme that combines fractional factorial design and stepwise regression is explored in this study. A potential advantage of MACO is that experiment trails are performed in parallel, which dramatically reduces the time required for determining a synergistic cocktail. In general, fractional factorial design is a statistical information-gathering strategy and has been widely applied in engineering research and industrial settings
[21],
[29]. Instead of brute-force or exhaustive search of all possible drug combinations, which are often impractical in many situations, fractional factorial design can dramatically reduce the number of experiments by defining trials that capture the individual and interactive effects on the response of a complex system. Based on the result, stepwise regression model building procedures can then be performed to extract the potential synergistic interactions between antibiotics.
In this study, the MACO scheme is studied for rapid screening of antimicrobial cocktails from a pool of natural and synthetic antimicrobials. In particular, pathogenic E. coli clinical isolates that cause urinary tract infection were chosen as the test organism in this study. A simplified 3-drug search experiment was first performed to illustrate the concept of the scheme for identifying synergistic antimicrobial cocktails. Antimicrobial cocktails were then searched from 5 drugs or 6 drugs to evaluate its robustness in determination of potent drug cocktails. A synergistic cocktail was identified in the study and was evaluated independently using several strains of E. coli clinical isolates to evaluate its general applicability. This study will potentially form the foundation of a statistical optimization approach for identifying synergistic antimicrobial cocktails toward the treatment of bacterial infections.